메뉴 건너뛰기




Volumn 1003, Issue , 2003, Pages 318-327

Converging Evidence of NMDA Receptor Hypofunction in the Pathophysiology of Schizophrenia

Author keywords

D cycloserine; D serine; Glycine; Glycine modulatory site; GlyT1; Negative symptoms; NMDA receptor; Schizophrenia

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR; CYCLOSERINE; GLYCINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEUROLEPTIC AGENT; PLACEBO; SARCOSINE; SERINE DERIVATIVE;

EID: 0347091918     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1196/annals.1300.020     Document Type: Conference Paper
Times cited : (371)

References (53)
  • 1
    • 0034843738 scopus 로고    scopus 로고
    • The emerging role of glutamate in the pathophysiology and treatment of schizophrenia
    • GOFF, D. & J.T. COYLE. 2001. The emerging role of glutamate in the pathophysiology and treatment of schizophrenia. Am. J. Psychiatry 158(9): 1367-1377.
    • (2001) Am. J. Psychiatry , vol.158 , Issue.9 , pp. 1367-1377
    • Goff, D.1    Coyle, J.T.2
  • 2
    • 0037308528 scopus 로고    scopus 로고
    • Genes for schizophrenia? Recent findings and their pathophysiological implications
    • HARRISON, P.J. & M.J. OWEN. 2003. Genes for schizophrenia? Recent findings and their pathophysiological implications. Lancet 361(9355): 417-419.
    • (2003) Lancet , vol.361 , Issue.9355 , pp. 417-419
    • Harrison, P.J.1    Owen, M.J.2
  • 3
    • 0033956237 scopus 로고    scopus 로고
    • Schizophrenia: Genes and environment
    • TSUANG, M. 2000. Schizophrenia: genes and environment. Biol. Psychiatry 47(3): 210-220.
    • (2000) Biol. Psychiatry , vol.47 , Issue.3 , pp. 210-220
    • Tsuang, M.1
  • 4
    • 0019462450 scopus 로고
    • Dopamine receptors, neuroleptics, and schizophrenia
    • SNYDER, S.H. 1981. Dopamine receptors, neuroleptics, and schizophrenia. Am. J. Psychiatry 138(4): 460-464.
    • (1981) Am. J. Psychiatry , vol.138 , Issue.4 , pp. 460-464
    • Snyder, S.H.1
  • 5
    • 0031417026 scopus 로고    scopus 로고
    • Treatment-resistant schizophrenia - The role of clozapine
    • MELTZER, H.Y. 1997. Treatment-resistant schizophrenia - the role of clozapine. Curr Med. Res. Opin. 14(1): 1-20.
    • (1997) Curr. Med. Res. Opin. , vol.14 , Issue.1 , pp. 1-20
    • Meltzer, H.Y.1
  • 6
    • 0014078609 scopus 로고
    • Effect of phencyclidine in chronic schizophrenics
    • ITIL, T. et al. 1967. Effect of phencyclidine in chronic schizophrenics. Can. Psychiatr. Assoc. J. 12(2): 209-212.
    • (1967) Can. Psychiatr. Assoc. J. , vol.12 , Issue.2 , pp. 209-212
    • Itil, T.1
  • 7
    • 70449240781 scopus 로고
    • Study of a new schizophrenomimetic drug - Sernyl
    • LUBY, E.D. et al. 1959. Study of a new schizophrenomimetic drug - sernyl. Arch. Neurol. Psychiatry 81: 363-369.
    • (1959) Arch. Neurol. Psychiatry , vol.81 , pp. 363-369
    • Luby, E.D.1
  • 8
    • 0025952455 scopus 로고
    • Recent advances in the phencyclidine model of schizophrenia
    • JAVITT, D.C. & S.R. ZUKIN. 1991. Recent advances in the phencyclidine model of schizophrenia. Am. J. Psychiatry 148(10): 1301-1308.
    • (1991) Am. J. Psychiatry , vol.148 , Issue.10 , pp. 1301-1308
    • Javitt, D.C.1    Zukin, S.R.2
  • 9
    • 0028323167 scopus 로고
    • Subanaesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses
    • KRYSTAL, J.H. et al. 1994. Subanaesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch. Gen. Psychiatry 51(3): 199-214.
    • (1994) Arch. Gen. Psychiatry , vol.51 , Issue.3 , pp. 199-214
    • Krystal, J.H.1
  • 10
    • 0030749913 scopus 로고    scopus 로고
    • Ketamine-induced exacerbation of psychotic symptoms and cognitive impairment in neuroleptic-free schizophrenics
    • MALHOTRA, A.K. et al. 1997. Ketamine-induced exacerbation of psychotic symptoms and cognitive impairment in neuroleptic-free schizophrenics. Neuropsychopharmacology 17(3): 141-150.
    • (1997) Neuropsychopharmacology , vol.17 , Issue.3 , pp. 141-150
    • Malhotra, A.K.1
  • 11
    • 0033080733 scopus 로고    scopus 로고
    • Ketamine-induced NMDA receptor hypofunction as a model of memory impairment and psychosis
    • NEWCOMER, J. et al. 1999. Ketamine-induced NMDA receptor hypofunction as a model of memory impairment and psychosis. Neuropsychopharmacology 20(2): 106-118.
    • (1999) Neuropsychopharmacology , vol.20 , Issue.2 , pp. 106-118
    • Newcomer, J.1
  • 12
    • 0036501435 scopus 로고    scopus 로고
    • Mismatch negativity predicts psychotic experiences induced by NMDA receptor antagonist in healthy volunteers
    • UMBRICHT, D. et al. 2002. Mismatch negativity predicts psychotic experiences induced by NMDA receptor antagonist in healthy volunteers. Biol. Psychiatry 51(5): 400-406.
    • (2002) Biol. Psychiatry , vol.51 , Issue.5 , pp. 400-406
    • Umbricht, D.1
  • 13
    • 0036711792 scopus 로고    scopus 로고
    • Effects of ketamine on leading saccades during smooth-pursuit eye movements may implicate cerebellar dysfunction in schizophrenia
    • AVILA, M.T. et al. 2002. Effects of ketamine on leading saccades during smooth-pursuit eye movements may implicate cerebellar dysfunction in schizophrenia. Am. J. Psychiatry 159(9): 1490-1496.
    • (2002) Am. J. Psychiatry , vol.159 , Issue.9 , pp. 1490-1496
    • Avila, M.T.1
  • 15
    • 0030900732 scopus 로고    scopus 로고
    • Activation of glutamatergic neurotransmission by ketamine: A novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex
    • MOGHADDAM, B. et al. 1997. Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. J. Neurosci. 17(8): 2921-2927.
    • (1997) J. Neurosci. , vol.17 , Issue.8 , pp. 2921-2927
    • Moghaddam, B.1
  • 16
    • 0034307054 scopus 로고    scopus 로고
    • Modulation of amphetamine-induced striatal dopamine release by ketamine in humans: Implications for schizophrenia
    • KEGELES, L.S. et al. 2000. Modulation of amphetamine-induced striatal dopamine release by ketamine in humans: implications for schizophrenia. Proc. Natl. Acad. Sci. USA 48(7): 627-640.
    • (2000) Proc. Natl. Acad. Sci. USA , vol.48 , Issue.7 , pp. 627-640
    • Kegeles, L.S.1
  • 17
    • 0034106451 scopus 로고    scopus 로고
    • Linking Hebb's coincidence-detection to memory formation
    • TSIEN, J.Z. 2000. Linking Hebb's coincidence-detection to memory formation. Curr. Opin. Neurobiol. 10(2): 266-273.
    • (2000) Curr. Opin. Neurobiol. , vol.10 , Issue.2 , pp. 266-273
    • Tsien, J.Z.1
  • 18
    • 0034712857 scopus 로고    scopus 로고
    • D-Serine is an endogenous ligand for the glycine site of the N-methyl-D-aspartate receptor
    • MOTHET, J.-P. et al. 2000. D-Serine is an endogenous ligand for the glycine site of the N-methyl-D-aspartate receptor. Proc. Natl. Acad. Sci. USA 97(9): 4926-4931.
    • (2000) Proc. Natl. Acad. Sci. USA , vol.97 , Issue.9 , pp. 4926-4931
    • Mothet, J.-P.1
  • 19
    • 0028348479 scopus 로고
    • Cloning of the human glycine transporter type 1: Molecular and pharmacological characterization of novel isoform variants and chromosomal localization of the gene in the human and mouse genomes
    • KIM, K.M. et al. 1994. Cloning of the human glycine transporter type 1: molecular and pharmacological characterization of novel isoform variants and chromosomal localization of the gene in the human and mouse genomes. Mol. Pharmacol. 45(4): 608-617.
    • (1994) Mol. Pharmacol. , vol.45 , Issue.4 , pp. 608-617
    • Kim, K.M.1
  • 20
    • 0032441894 scopus 로고    scopus 로고
    • Modulation of N-methyl-D-aspartate receptor function by glycine transport
    • BERGERON, R. et al. 1998. Modulation of N-methyl-D-aspartate receptor function by glycine transport. Proc. Natl. Acad. Sci. USA 95(26): 15730-15734.
    • (1998) Proc. Natl. Acad. Sci. USA , vol.95 , Issue.26 , pp. 15730-15734
    • Bergeron, R.1
  • 21
    • 0032415129 scopus 로고    scopus 로고
    • Glycine uptake governs glycine site occupancy at NMDA receptors of excitatory synapses
    • BERGER, A.J. et al. 1998. Glycine uptake governs glycine site occupancy at NMDA receptors of excitatory synapses. J. Neurophysiol. 80(6): 3336-3340.
    • (1998) J. Neurophysiol. , vol.80 , Issue.6 , pp. 3336-3340
    • Berger, A.J.1
  • 22
    • 0037320805 scopus 로고    scopus 로고
    • Glycine transporter-1 blockade potentiates NMDA-mediated responses in rat prefrontal cortical neurons in vitro and in vivo
    • CHEN, L. et al. 2003. Glycine transporter-1 blockade potentiates NMDA-mediated responses in rat prefrontal cortical neurons in vitro and in vivo. J. Neurophysiol. 89(2): 691-703.
    • (2003) J. Neurophysiol. , vol.89 , Issue.2 , pp. 691-703
    • Chen, L.1
  • 23
    • 0035477818 scopus 로고    scopus 로고
    • Increased cortical kynurenate content in schizophrenia
    • SCHWARCZ, R. et al. 2001. Increased cortical kynurenate content in schizophrenia. Biol. Psychiatry 50(7): 521-530.
    • (2001) Biol. Psychiatry , vol.50 , Issue.7 , pp. 521-530
    • Schwarcz, R.1
  • 24
    • 0033530857 scopus 로고    scopus 로고
    • Glutamate carboxypeptidase II is expressed by astrocytes in the rat nervous system
    • BERGER, U.V. et al. 1999. Glutamate carboxypeptidase II is expressed by astrocytes in the rat nervous system. J. Comp. Neurol. 415: 52-64.
    • (1999) J. Comp. Neurol. , vol.415 , pp. 52-64
    • Berger, U.V.1
  • 25
    • 0028875197 scopus 로고
    • Abnormal excitatory neurotransmitter metabolism in schizophrenic brains
    • TSAI, G. et al. 1995. Abnormal excitatory neurotransmitter metabolism in schizophrenic brains. Arch. Gen. Psychiatry 52(10): 829-836.
    • (1995) Arch. Gen. Psychiatry , vol.52 , Issue.10 , pp. 829-836
    • Tsai, G.1
  • 26
    • 0035836642 scopus 로고    scopus 로고
    • Genome-wide expression analysis reveals dysregulation of myelination-related genes in chronic schizophrenia
    • HAKAK, Y. et al. 2001. Genome-wide expression analysis reveals dysregulation of myelination-related genes in chronic schizophrenia. Proc. Natl. Acad. Sci. USA 98(8): 4746-4751.
    • (2001) Proc. Natl. Acad. Sci. USA , vol.98 , Issue.8 , pp. 4746-4751
    • Hakak, Y.1
  • 27
    • 0035098294 scopus 로고    scopus 로고
    • Beta-NAAG rescues LTP from blockade by NAAG in rat dentate gyrus via the type 3 metabotropic glutamate receptor
    • LEA, P.M. IV et al. 2001 beta-NAAG rescues LTP from blockade by NAAG in rat dentate gyrus via the type 3 metabotropic glutamate receptor. J. Neurophysiol. 85(3): 1097-1106.
    • (2001) J. Neurophysiol. , vol.85 , Issue.3 , pp. 1097-1106
    • Lea IV, P.M.1
  • 28
    • 38149138747 scopus 로고    scopus 로고
    • Metabotropic glutamate receptor 3 (GRM3) gene variation is not associated with schizophrenia or bipolar affective disorder in the German population
    • MARTI, S.B. et al. 2002. Metabotropic glutamate receptor 3 (GRM3) gene variation is not associated with schizophrenia or bipolar affective disorder in the German population. Am. J. Med. Genet. 114(1): 46-50.
    • (2002) Am. J. Med. Genet. , vol.114 , Issue.1 , pp. 46-50
    • Marti, S.B.1
  • 29
    • 0037108758 scopus 로고    scopus 로고
    • Genetic and physiological data implicating the new human gene G72 and the gene for D-amino acid oxidase in schizophrenia
    • CHUMAKOV, I. et al. 2002 Genetic and physiological data implicating the new human gene G72 and the gene for D-amino acid oxidase in schizophrenia. Proc. Natl. Acad. Sci. USA 99(21): 13675-13680.
    • (2002) Proc. Natl. Acad. Sci. USA , vol.99 , Issue.21 , pp. 13675-13680
    • Chumakov, I.1
  • 30
    • 0037977113 scopus 로고    scopus 로고
    • Decreased serum levels of D-serine in patients with schizophrenia: Evidence in support of the N-methyl-D-aspartate receptor hypofunction hypothesis of schizophrenia
    • HASHIMOTO, K. et al. 2003. Decreased serum levels of D-serine in patients with schizophrenia: evidence in support of the N-methyl-D-aspartate receptor hypofunction hypothesis of schizophrenia. Arch. Gen. Psychiatry 60(6): 572-576.
    • (2003) Arch. Gen. Psychiatry , vol.60 , Issue.6 , pp. 572-576
    • Hashimoto, K.1
  • 31
    • 0035368610 scopus 로고    scopus 로고
    • Receptor signaling pathways in the nervous system
    • BUONANNO, A. et al. 2001 Receptor signaling pathways in the nervous system. Curr. Opin. Neurobiol. 11(3): 287-296.
    • (2001) Curr. Opin. Neurobiol. , vol.11 , Issue.3 , pp. 287-296
    • Buonanno, A.1
  • 32
    • 0013375948 scopus 로고    scopus 로고
    • Neuregulin 1 and susceptibility to schizophrenia
    • STEFANSSON, H. et al. 2002. Neuregulin 1 and susceptibility to schizophrenia. Am. J. Hum. Genet. 71(4): 877-892.
    • (2002) Am. J. Hum. Genet. , vol.71 , Issue.4 , pp. 877-892
    • Stefansson, H.1
  • 33
    • 0030044715 scopus 로고    scopus 로고
    • The glutamatergic dysfunction hypothesis for schizophrenia
    • COYLE, J.T. 1996. The glutamatergic dysfunction hypothesis for schizophrenia. Harvard Rev. Psychiatry 3(5): 241-253.
    • (1996) Harvard Rev. Psychiatry , vol.3 , Issue.5 , pp. 241-253
    • Coyle, J.T.1
  • 34
    • 0029880412 scopus 로고    scopus 로고
    • NMDA-dependent modulation of CA1 local circuit inhibition
    • GRUNZE, H.C. et al. 1996. NMDA-dependent modulation of CA1 local circuit inhibition. J. Neurosci. 16(6): 2034-2043.
    • (1996) J. Neurosci. , vol.16 , Issue.6 , pp. 2034-2043
    • Grunze, H.C.1
  • 35
    • 0029646097 scopus 로고
    • Age-specific neurotoxicity in the rat associated with NMDA receptor blockade: Potential relevance to schizophrenia?
    • FARBER, N.B. et al. 1995. Age-specific neurotoxicity in the rat associated with NMDA receptor blockade: potential relevance to schizophrenia? Biol. Psychiatry 15: 788-796.
    • (1995) Biol. Psychiatry , vol.15 , pp. 788-796
    • Farber, N.B.1
  • 36
    • 0037092430 scopus 로고    scopus 로고
    • NMDA receptor antagonists disinhibit rat posterior cingulate and retrosplenial cortices: A potential mechanism of neurotoxicity
    • LI, Q. et al. 2002. NMDA receptor antagonists disinhibit rat posterior cingulate and retrosplenial cortices: a potential mechanism of neurotoxicity. J. Neurosci. 22: 3070-3080.
    • (2002) J. Neurosci. , vol.22 , pp. 3070-3080
    • Li, Q.1
  • 37
    • 0033759439 scopus 로고    scopus 로고
    • Decrease in reelin and glutamic acid decarboxylase67 (GAD 67) expression in schizophrenia and bipolar disorder: A postmortem study
    • GUIDOTTI, A. et al. 2000. Decrease in reelin and glutamic acid decarboxylase67 (GAD 67) expression in schizophrenia and bipolar disorder: A postmortem study. Arch. Gen Psychiatry 57(11): 1061-1069.
    • (2000) Arch. Gen Psychiatry , vol.57 , Issue.11 , pp. 1061-1069
    • Guidotti, A.1
  • 38
    • 0034011252 scopus 로고    scopus 로고
    • Decreased glutamic acid decarboxylase67 messenger RNA expression in a subset of prefrontal cortical gamma-aminobutyric acid neurons in subjects with schizophrenia
    • VOLK, D. et al. 2000. Decreased glutamic acid decarboxylase67 messenger RNA expression in a subset of prefrontal cortical gamma-aminobutyric acid neurons in subjects with schizophrenia. Arch. Gen Psychiatry 57: 237-245.
    • (2000) Arch. Gen Psychiatry , vol.57 , pp. 237-245
    • Volk, D.1
  • 39
    • 0035140656 scopus 로고    scopus 로고
    • GABa transporter-1 mRNA in prefrontal cortex in schizophrenia: Decreased expression in a subset of neurons
    • VOLK, D. et al. 2001. GABA transporter-1 mRNA in prefrontal cortex in schizophrenia: decreased expression in a subset of neurons. Am. J. Psychiatry 158(2): 256-265.
    • (2001) Am. J. Psychiatry , vol.158 , Issue.2 , pp. 256-265
    • Volk, D.1
  • 40
    • 0036784474 scopus 로고    scopus 로고
    • Reciprocal alterations in pre- and post-synaptic inhibitory markers at chandler cell inputs to pyramidal neurons in schizophrenia
    • VOLK, D.W. et al. 2002. Reciprocal alterations in pre-and post-synaptic inhibitory markers at chandler cell inputs to pyramidal neurons in schizophrenia. Cereb. Cortex 12(10): 1063-1070.
    • (2002) Cereb. Cortex , vol.12 , Issue.10 , pp. 1063-1070
    • Volk, D.W.1
  • 41
    • 0030331175 scopus 로고    scopus 로고
    • Up-regulation of GABAA receptor binding on neurons of the prefrontal cortex in schizophrenic subjects
    • BENES, F.M. et al. 1996. Up-regulation of GABAA receptor binding on neurons of the prefrontal cortex in schizophrenic subjects. Neuroscience 75(4): 1021-1031.
    • (1996) Neuroscience , vol.75 , Issue.4 , pp. 1021-1031
    • Benes, F.M.1
  • 42
    • 0037441519 scopus 로고    scopus 로고
    • Comparative genome- and proteome analysis of cerebral cortex from MK-801-treated rats
    • PAULSON, L. et al. 2003. Comparative genome-and proteome analysis of cerebral cortex from MK-801-treated rats. J. Neurosci. Res. 71(4): 526-533.
    • (2003) J. Neurosci. Res. , vol.71 , Issue.4 , pp. 526-533
    • Paulson, L.1
  • 43
    • 0037942706 scopus 로고    scopus 로고
    • Ionotropic glutamate receptors as therapeutic targets in schizophrenia
    • COYLE, J.T. et al. 2002. Ionotropic glutamate receptors as therapeutic targets in schizophrenia. Curr. Drug Targets CNS Neurol. Disorders 1: 183-189.
    • (2002) Curr. Drug Targets CNS Neurol. Disorders , vol.1 , pp. 183-189
    • Coyle, J.T.1
  • 44
    • 0033558578 scopus 로고    scopus 로고
    • AE Bennett Research Award. Reversal of phencyclidine-induced effects by glycine and glycine transport inhibitors
    • JAVITT, D.C. et al. 1999. AE Bennett Research Award. Reversal of phencyclidine-induced effects by glycine and glycine transport inhibitors. Biol. Psychiatry 45(6): 668-679.
    • (1999) Biol. Psychiatry , vol.45 , Issue.6 , pp. 668-679
    • Javitt, D.C.1
  • 45
    • 0032925438 scopus 로고    scopus 로고
    • Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia
    • HERESCO-LEVY, U. et al. 1999. Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia. Arch. Gen. Psychiatry 56(1): 29-36.
    • (1999) Arch. Gen. Psychiatry , vol.56 , Issue.1 , pp. 29-36
    • Heresco-Levy, U.1
  • 46
    • 0032403626 scopus 로고    scopus 로고
    • D-Serine added to antipsychotics for the treatment of schizophrenia
    • TSAI, G. et al. 1998. D-Serine added to antipsychotics for the treatment of schizophrenia. Biol. Psychiatry 44(11): 1081-1089.
    • (1998) Biol. Psychiatry , vol.44 , Issue.11 , pp. 1081-1089
    • Tsai, G.1
  • 47
    • 0034898096 scopus 로고    scopus 로고
    • Subunit specificity and mechanism of action of NMDA partial agonist D-cycloserine
    • SHEININ, A. et al. 2001. Subunit specificity and mechanism of action of NMDA partial agonist D-cycloserine. Neuropharmacology 41(2): 151-158.
    • (2001) Neuropharmacology , vol.41 , Issue.2 , pp. 151-158
    • Sheinin, A.1
  • 48
    • 0037008687 scopus 로고    scopus 로고
    • Direct calcium binding results in activation of brain serine racemase
    • COOK, S.P. et al. 2002. Direct calcium binding results in activation of brain serine racemase. J. Biol. Chem. 277: 27782-27792.
    • (2002) J. Biol. Chem. , vol.277 , pp. 27782-27792
    • Cook, S.P.1
  • 49
    • 0029116094 scopus 로고
    • Dose-finding trial of D-cycloserine added to neuroleptics for negative symptoms in schizophrenia
    • GOFF, D.C, et al. 1995. Dose-finding trial of D-cycloserine added to neuroleptics for negative symptoms in schizophrenia. Am. J. Psychiatry 152(8): 1213-1215.
    • (1995) Am. J. Psychiatry , vol.152 , Issue.8 , pp. 1213-1215
    • Goff, D.C.1
  • 50
    • 0032902238 scopus 로고    scopus 로고
    • A placebo-controlled trial of D-cycloserine added to conventional neuroleptics in patients with schizophrenia
    • GOFF, D.C. et al. 1999. A placebo-controlled trial of D-cycloserine added to conventional neuroleptics in patients with schizophrenia. Arch. Gen. Psychiatry 56(1): 21-27.
    • (1999) Arch. Gen. Psychiatry , vol.56 , Issue.1 , pp. 21-27
    • Goff, D.C.1
  • 51
    • 0036184549 scopus 로고    scopus 로고
    • Placebo-controlled trial of D-cycloserine added to conventional neuroleptics, olanzapine, or risperidone in schizophrenia
    • HORESCO-LEVY, U. et al. 2002. Placebo-controlled trial of D-cycloserine added to conventional neuroleptics, olanzapine, or risperidone in schizophrenia. Am. J. Psychiatry 159: 480-482.
    • (2002) Am. J. Psychiatry , vol.159 , pp. 480-482
    • Horesco-Levy, U.1
  • 52
    • 0345899818 scopus 로고    scopus 로고
    • Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for treatment of schizophrenia
    • In press
    • TSAI, G. et al. 2003. Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for treatment of schizophrenia. Biol. Psychiatry. In press.
    • (2003) Biol. Psychiatry.
    • Tsai, G.1
  • 53
    • 0041653565 scopus 로고    scopus 로고
    • Progressive decrease of left Heschl gyrus and planum temporale gray matter volume in first-episode schizophrenia: A longitudinal magnetic resonance imaging study
    • KASAI, K. et al. 2003. Progressive decrease of left Heschl gyrus and planum temporale gray matter volume in first-episode schizophrenia: a longitudinal magnetic resonance imaging study. Arch. Gen. Psychiatry 60(8): 766-775.
    • (2003) Arch. Gen. Psychiatry , vol.60 , Issue.8 , pp. 766-775
    • Kasai, K.1


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.